COVID-19 vaccines work—but immunocompromised individuals may not produce as strong an immune response. Evusheld became the first treatment to protect this group before exposure to the virus when it received emergency authorization from the FDA in December 2021. The antibody therapy—made by AstraZeneca and given by injection to people at high risk of developing serious disease if they get COVID-19—is a combination of two monoclonal antibodies that soak up virus proteins to prevent them from infecting healthy cells. There is a downside of antibody-based treatments like Evusheld, however: viruses can mutate to become resistant to them. The FDA has warned that the therapy might not be as effective with newer Omicron variants compared to previous strains of SARS-CoV-2.
- Why Trump’s Message Worked on Latino Men
- What Trump’s Win Could Mean for Housing
- The 100 Must-Read Books of 2024
- Sleep Doctors Share the 1 Tip That’s Changed Their Lives
- Column: Let’s Bring Back Romance
- What It’s Like to Have Long COVID As a Kid
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
